Multinational clinical studies may not require bridge tests.

The bridge test could be exempted when the local drug company conducted a multinational clinical studies at the time of new drug development, and it is possible for any new drugs developed in the overseas to conduct multicenter clinical studies in Korean test institutes.

When a new drug already approved in foreign countries tries to apply its registration in Korea, only pharmacokinetic tes...